Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
JPMorgan Chase & Co. Third Quarter 2025 Earnings Call - Markets and Fee Strength Mask Rising RWA, Fraud-Related Losses, and Cautious 2026 NII/Expense Outlook
JPMorgan reported a strong quarter: $14.4 billion in net income, $47.1 billion of revenue and double-digit gains in markets, investment banking, payments and asset management. But under the surface th...
- Net income $14.4 billion, EPS $5.07, ROTC 20% for Q3 2025; revenue $47.1 billion, up 9% year on year, driven largely by markets and higher fees across IB, AWM and payments.
- Net interest income dynamics mixed: balance sheet growth and mix helped NII this quarter, but lower rates were a headwind; Q4 NII ex-markets guidance ~ $23.5 billion, Q4 total NII ~ $25 billion.
- Management provided a 2026 central case for NII ex Markets of about $95 billion, labeled preliminary and subject to the budget cycle and macro moves.
- +17 more takeaways
Goldman Sachs Q3 2025 Earnings Call - Dominant M&A, record AWM flows, and One Goldman Sachs 3.0 AI efficiency push
Goldman Sachs reported a strong Q3 2025: $15.2 billion of net revenues, $12.25 EPS, and mid-teens returns as its market-leading M&A franchise and markets businesses powered performance. The firm flagg...
- Net revenues of $15.2 billion and EPS of $12.25 in Q3 2025, delivering a reported ROE of 14.2% (ROTE 15.2% per CFO commentary).
- Goldman declared market leadership in M&A, advising on over $1 trillion of announced M&A year to date, roughly $220 billion ahead of its nearest competitor.
- Advisory revenues were $1.4 billion, up 60% year over year, and quarter-end investment banking backlog is the highest in three years.
- +17 more takeaways
Simply Good Foods Company Q3 FY2025 Earnings Call - Quest and OWYN Power Growth as Atkins Faces Distribution Cuts and Margin Pressure
Simply Good Foods reported steady top-line momentum in Q3 FY2025, with net sales up ~14% to $381 million driven by the OWYN acquisition and roughly 4% organic growth. Quest and OWYN delivered double-d...
- Q3 net sales rose 13.8% year over year to $381 million, driven by OWYN contribution (~$33.6 million) and about 3.8% organic growth.
- Quest and OWYN together represent ~70% of net sales and delivered double-digit consumption growth in Q3; Quest consumption +11% and OWYN retail takeaway +24%.
- Atkins consumption declined ~13% year over year in Q3, largely due to distribution losses at a key customer and non-repeating merchandising events.
- +12 more takeaways
Rocky Mountain Chocolate Factory Q2 2026 Earnings Call - From Turnaround to Execution, Franchise Growth and Operational Fixes Take Center Stage
Management says the heavy lifting of a 16-month turnaround is largely complete and the company is shifting from planning to disciplined execution, with a new operating team, a refreshed brand, and a p...
- Management says 16 months of modernization are largely complete and the firm is shifting from transformation plans to focused execution across operations, franchise support, and brand presentation.
- Total revenue was $6.8 million in the quarter, up from $6.4 million year over year; product sales were $5.2 million versus $4.9 million and franchise and royalty fees were $1.6 million versus $1.5 million.
- Total product and retail gross profit was negative $33,000, driven by timing of inventory adjustments and comparability factors, partially offset by factory efficiency gains.
- +13 more takeaways
FB Financial Corporation Q3 2025 Earnings Call - Southern States Merger Lifts Margin, Accelerates Synergies and Boosts Adjusted EPS
FB Financial closed the Southern States Bancshares deal July 1 and completed systems conversion over Labor Day, reporting the first quarter as a combined company. The headline: adjusted EPS jumped to ...
- Q3 was the first full quarter including Southern States Bancshares, transaction closed July 1 and systems conversion completed by Labor Day, operating as one brand from Sept 2.
- Reported EPS for the quarter was $0.43, adjusted EPS was $1.07, reflecting merger impacts and other non-GAAP adjustments.
- Net interest income was $147.2 million, up 32.2% sequentially and 38.9% year over year, with NIM expanding to 3.95% from 3.68% (a 27 bps lift).
- +14 more takeaways
WD-40 Company Third Quarter Fiscal Year 2025 Earnings Call - Record sales and gross margin recovery to 56% one year ahead
WD-40 reported a record third quarter of $156.9 million in sales, but growth was modest, up 1% year over year, or 2% on an estimated constant currency basis. The bigger development is margin, not top ...
- Record Q3 net sales of $156.9 million, up 1% year over year, or $158.6 million and +2% when adjusting for estimated translation impacts of foreign currency.
- Maintenance products remain the core focus, with Q3 maintenance net sales of $150.4 million, up 2% year over year, and year to date maintenance sales of $435.2 million, up 6% and in line with mid-to-high single-digit long-term targets.
- Gross margin expanded to 56.2% in Q3, a 310 basis point improvement versus prior year, driven by higher selling prices (+110 bps), lower specialty chemical costs (+80 bps), and reduced can costs (+60 bps); full-year gross margin guided to 55% to 56%.
- +11 more takeaways
Johnson & Johnson Q3 2025 Earnings Call - Momentum: New launches and a MedTech reshuffle offset Stelara loss of exclusivity
Johnson & Johnson reported a strong Q3 2025, with $24 billion in sales and 5.4% operational growth, driven by an aggressive new-product cadence across oncology, immunology, neuroscience, cardiovascula...
- Q3 topline: $24.0 billion in sales, 5.4% operational growth despite an approximate 640-basis-point headwind from Stelara loss of exclusivity.
- Innovative Medicine: $15.6 billion, up 5.3% operationally, with a cited ~1,070-basis-point Stelara headwind in that segment yet still showing robust in-market momentum.
- MedTech: $8.4 billion, up 5.6% operationally, with strength in cardiovascular, electrophysiology, vision and shockwave technologies.
- +12 more takeaways
Senseonics Second Quarter 2025 Earnings Call - Eversense 365 Launch Accelerates, $77.8M Raised to Fund DTC Push and Pipeline
Senseonics reported clear commercial momentum for Eversense 365, with new patient starts rising 79% year over year and 37% sequentially, and leads more than doubling versus last year. Management raise...
- New patient momentum: Eversense 365 new patient starts rose 79% year over year and 37% sequentially in Q2, with leads more than doubling versus prior year and June leads 50% above the prior three month average.
- Financing bolsters runway: Senseonics raised approximately $77.8 million in gross proceeds in Q2, including a $20 million concurrent placement with Abbott, leaving cash, restricted cash and equivalents of about $126.7 million as of June 30, 2025.
- Planned DTC acceleration: Company will more than double previously planned direct to consumer spend with Ascensia, committing over $10 million across the next two quarters to boost leads and conversions.
- +12 more takeaways
CareDx Q2 2025 Earnings Call - Volume and profitability rebound met by looming Medicare LCD risk
CareDx reported a clear operational rebound in Q2 2025: adjusted revenue of $90.5M, testing volume of ~49,500 results (up 13% YoY), and adjusted EBITDA of $9.1M versus a loss in the year-ago quarter. ...
- Adjusted revenue (ex. prior-period tests) was $90.5M in Q2 2025, up 14% year over year; reported revenue was $86.7M after a $3.8M prior-period test write-off.
- Adjusted EBITDA improved to $9.1M in Q2 2025, vs an adjusted loss of $0.3M in Q2 2024, driven by volume growth and operating leverage.
- Testing services delivered ~49,500 test results in the quarter, up 13% YoY, marking the eighth consecutive quarter of sequential testing volume growth.
- +13 more takeaways
Universal Technical Institute Third Quarter 2025 Earnings Call - Concord Growth Restrictions Lifted, Raises 2025 Guidance
Universal Technical Institute turned in a tidy quarter, with revenue up 15% and adjusted EBITDA up 37% as demand for skilled trades and allied health programs remained strong. Management used the call...
- Revenue rose 15.1% year over year to $204.3 million in Q3 2025, beating expectations and showing sustained top line momentum.
- Adjusted EBITDA increased 37.3% year over year to $25.3 million, a big operational beat, though comparisons are complicated by accounting and investment timing changes.
- Net income was $10.7 million, up roughly 114% year over year, with diluted EPS of $0.19 for the quarter.
- +15 more takeaways